Cargando…

The dark side of opioids in pain management: basic science explains clinical observation

INTRODUCTION: In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer. OBJECTIVES: We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivat, Cyril, Ballantyne, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741356/
https://www.ncbi.nlm.nih.gov/pubmed/29392193
http://dx.doi.org/10.1097/PR9.0000000000000570
_version_ 1783288183298981888
author Rivat, Cyril
Ballantyne, Jane
author_facet Rivat, Cyril
Ballantyne, Jane
author_sort Rivat, Cyril
collection PubMed
description INTRODUCTION: In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer. OBJECTIVES: We aimed to examine the published literature on basic science explaining pronociceptive opioid actions, and apply this knowledge to clinical observation. METHODS: We reviewed the existing literature on the pronociceptive actions of opioids, both preclinical and clinical studies. RESULTS: Basic science provides a rationale for the clinical observation that opioids sometimes increase rather than decrease pain. Central sensitization (hyperalgesia) underlies pain chronification, but can also be produced by high dose and high potency opioids. Many of the same mechanisms account for both central pain and opioid hyperalgesia. CONCLUSION: Newly revealed basic mechanisms suggest possible avenues for drug development and new drug therapies that could alter pain sensitization through endogenous and exogenous opioid mechanisms. Recent changes in practice such as the introduction of titration-to-effect for opioids have resulted in higher doses used in the clinic setting than ever seen previously. New basic science knowledge hints that these newer dosing practices may need to be reexamined. When pain worsens in a patient taking opioids, can we be assured that this is not because of the opioids, and can we alter this negative effect of opioids through different dosing strategies or new drug intervention?
format Online
Article
Text
id pubmed-5741356
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-57413562018-02-01 The dark side of opioids in pain management: basic science explains clinical observation Rivat, Cyril Ballantyne, Jane Pain Rep Inaugural Review Series INTRODUCTION: In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer. OBJECTIVES: We aimed to examine the published literature on basic science explaining pronociceptive opioid actions, and apply this knowledge to clinical observation. METHODS: We reviewed the existing literature on the pronociceptive actions of opioids, both preclinical and clinical studies. RESULTS: Basic science provides a rationale for the clinical observation that opioids sometimes increase rather than decrease pain. Central sensitization (hyperalgesia) underlies pain chronification, but can also be produced by high dose and high potency opioids. Many of the same mechanisms account for both central pain and opioid hyperalgesia. CONCLUSION: Newly revealed basic mechanisms suggest possible avenues for drug development and new drug therapies that could alter pain sensitization through endogenous and exogenous opioid mechanisms. Recent changes in practice such as the introduction of titration-to-effect for opioids have resulted in higher doses used in the clinic setting than ever seen previously. New basic science knowledge hints that these newer dosing practices may need to be reexamined. When pain worsens in a patient taking opioids, can we be assured that this is not because of the opioids, and can we alter this negative effect of opioids through different dosing strategies or new drug intervention? Wolters Kluwer 2016-09-08 /pmc/articles/PMC5741356/ /pubmed/29392193 http://dx.doi.org/10.1097/PR9.0000000000000570 Text en Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Inaugural Review Series
Rivat, Cyril
Ballantyne, Jane
The dark side of opioids in pain management: basic science explains clinical observation
title The dark side of opioids in pain management: basic science explains clinical observation
title_full The dark side of opioids in pain management: basic science explains clinical observation
title_fullStr The dark side of opioids in pain management: basic science explains clinical observation
title_full_unstemmed The dark side of opioids in pain management: basic science explains clinical observation
title_short The dark side of opioids in pain management: basic science explains clinical observation
title_sort dark side of opioids in pain management: basic science explains clinical observation
topic Inaugural Review Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741356/
https://www.ncbi.nlm.nih.gov/pubmed/29392193
http://dx.doi.org/10.1097/PR9.0000000000000570
work_keys_str_mv AT rivatcyril thedarksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation
AT ballantynejane thedarksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation
AT rivatcyril darksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation
AT ballantynejane darksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation